SciBX: Science-Business eXchange Contents: 12 08 2011, Volume 4 / Issue 47

TABLE OF CONTENTS December 8 2011, Volume 4 / Issue 47 Analysis Cover Story Targets and Mechanisms The Distillery: Therapeutics Cancer Cardiovascular disease Dermatology Endocrine/metabolic disease Infectious disease Neurology Other Various The Distillery: Techniques Disease models Drug platforms Advertisement SciBX: Science-Business eXchange Recommend SciBX to your library today SciBx is a weekly publication that identifies and analyzes the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why. Subscribe to SciBX and you won't miss the next big thing. For more information visit: www.nature.com/scibx.   Trade Secrets A Nature Network blog by BIOENTREPRENEUR Brought to you by Nature Biotechnology Access the insights, advice and commentary from scientists and entrepreneurs building biotech sectors around the world. Join the global dialogue on life science entrepreneurship: http://blogs.nature.com/trade_secrets   Analysis Cover Story Top Big MAC attack in osteoarthritis Michael J. Haas doi:10.1038/scibx.2011.1311 An international team has shown that inhibiting the complement system could help slow disease progression in osteoarthritis, thus handing a potentially disease-modifying strategy to companies developing complement 5 inhibitors. Full Text | PDF Targets and Mechanisms Top Xa and IX mark the clot Kai-Jye Lou doi:10.1038/scibx.2011.1312 Two groups have engineered clotting factor variants that could help correct coagulation defects in hemophilia. Pfizer has exclusively licensed one of the factors, and an undisclosed company has licensed the other. Full Text | PDF Proteasome DUBstep Chris Cain doi:10.1038/scibx.2011.1313 Karolinska researchers have identified a small molecule cancer compound that inhibits two deubiquitinating enzymes associated with the proteasome. Vivolux has licensed the candidate and is performing lead optimization. Full Text | PDF FLATtening pain Lev Osherovich doi:10.1038/scibx.2011.1314 Researchers have discovered a transporter protein called FLAT that helps inactivate a naturally occurring analgesic. The team has created a small molecule antagonist of FLAT that could be useful for treating pain. Full Text | PDF Distillery: Therapeutics Cancer Top IL-11 receptor-α (IL11RA) doi:10.1038/scibx.2011.1315 In vitro, mouse and patient sample studies suggest T cells modified to express IL11RA could help treat osteosarcoma. Full Text | PDF Microtubule associated serine/threonine kinase 1 (MAST1); MAST2 doi:10.1038/scibx.2011.1316 Genomic analysis and mouse studies suggest inhibiting MAST1 or MAST2 could help treat a subset of breast cancers. Full Text | PDF Annexin A1 (ANXA1) doi:10.1038/scibx.2011.1317 Studies in mice identified an ANXA1-targeted peptide that could help treat cancer. Full Text | PDF Heat shock protein 90 (Hsp90) doi:10.1038/scibx.2011.1318 Mouse studies identified 3,4-isoxazolediamide–based Hsp90 inhibitors that could help treat cancer. Full Text | PDF Not applicable doi:10.1038/scibx.2011.1319 A study in mice suggests antioxidants could help treat cancer by stopping the suppression of the immune system by myeloid-derived suppressor (MDS) cells. Full Text | PDF Thioredoxin; NF-κB doi:10.1038/scibx.2011.1320 In vitro and mouse studies suggest a class of NSAID analogs could help treat cancer. Full Text | PDF Tumor necrosis factor–related apoptosis-inducing ligand (TRAIL); TRAIL receptor 2 (TRAIL-R2) doi:10.1038/scibx.2011.1321 Cell culture studies suggest wogonin and its related flavone derivatives could help overcome TRAIL resistance in cancer. Full Text | PDF Chaperone-mediated autophagy doi:10.1038/scibx.2011.1322 Mouse studies suggest inhibition of chaperone-mediated autophagy could help treat lung cancer. Full Text | PDF Dickkopf homolog 1 (DKK1) doi:10.1038/scibx.2011.1323 Studies in mice suggest DKK1 vaccination could help treat MM. Full Text | PDF Pim-1 (PIM1); B cell lymphoma 2 (BCL-2; BCL2) doi:10.1038/scibx.2011.1324 Cell culture and mouse studies suggest combining PIM1 and BCL2 inhibitors could help treat prostate cancer. Full Text | PDF Cardiovascular disease Top NLR family pyrin domain containing 3 (NLRP3; NALP3); purinergic receptor P2X ligand-gated ion channel 7 (P2RX7; P2X7) doi:10.1038/scibx.2011.1325 In vitro and mouse studies suggest inhibiting inflammasome components after acute MI could help decrease damage and prevent heart failure. Full Text | PDF Seven in absentia homolog 2 (SIAH2) doi:10.1038/scibx.2011.1326 In vitro and mouse studies suggest inhibiting SIAH2 could help treat MI-induced ischemia/reperfusion injury. Full Text | PDF Dermatology Top Killer cell lectin-like receptor subfamily K member 1 (KLRK1; CD314; NKG2D); T cell receptor (TCR); RNA export 1 homolog (RAE1); CD3d molecule-δ CD3-TCR complex (CD3D) doi:10.1038/scibx.2011.1327 Mouse studies suggest inhibiting signaling between NKG2D ligands such as RAE1 and γδTCR on T cells could help treat atopic dermatitis. Full Text | PDF Endocrine/metabolic disease Top Hepatocyte growth factor/scatter factor (HGF/SF) doi:10.1038/scibx.2011.1328 Studies in cell culture and in mice suggest HGF/SF could help treat type 2 diabetes. Full Text | PDF Infectious disease Top Not applicable doi:10.1038/scibx.2011.1329 In vitro studies suggest a class of cyclic peptides could help treat HCV infection. Full Text | PDF Unknown doi:10.1038/scibx.2011.1330 Mouse studies identified an imidazolopiperazine-based compound that could help treat malaria. Full Text | PDF Not applicable doi:10.1038/scibx.2011.1331 Mouse studies suggest Gleevec imatinib could help treat Mycobacterium tuberculosis infection. Full Text | PDF Bacterial fimbrial adhesin (fimH) doi:10.1038/scibx.2011.1332 Studies in mice suggest mannoside-based inhibitors of Escherichia coli fimH could help treat UTI. Full Text | PDF Neurology Top β-Amyloid (Aβ) doi:10.1038/scibx.2011.1333 In vitro and cell culture studies suggest increasing Ab polymerization could help treat AD. Full Text | PDF FAAH-like anandamide transporter (FLAT) doi:10.1038/scibx.2011.1334 Cell culture and rodent studies suggest antagonizing FLAT could be useful for treating pain. Full Text | PDF μ-Opioid receptor (OPRM1; MOR) doi:10.1038/scibx.2011.1335 In vitro studies identified a naltrexone-derived opioid that could help treat pain without opiate-associated side effects. Full Text | PDF Other Top Transmembrane channel-like-1 (TMC1); TMC2 doi:10.1038/scibx.2011.1336 Mouse studies suggest increasing TMC1 or TMC2 expression in patients with hearing loss caused by TMC1 mutations could help restore hearing. Full Text | PDF Various Top NLR family pyrin domain containing 12 (NLRP12; NALP12) doi:10.1038/scibx.2011.1337 Mouse studies suggest increasing NLRP12 signaling could help prevent colitis and colitis-associated tumorigenesis. Full Text | PDF Distillery: Techniques Disease models Top K-Ras-mutant, cyclin dependent kinase inhibitor 2A (Cdkn2a; Ink4a; Arf; p16ink4a)-deficient mouse cell model of sarcoma doi:10.1038/scibx.2011.1338 Mouse muscle-associated cells engineered to express a mutant K-Ras and to be deficient in p16ink4a could aid the development of new therapies for sarcomas. Full Text | PDF Drug platforms Top Trypanosoma cruzi expressing cancer/testis antigen 1B (CTAG1B; NY-ESO-1) as an anticancer vaccine vector doi:10.1038/scibx.2011.1339 A highly attenuated T. cruzi strain expressing the cancer testis antigen NY-ESO-1 could be used as a vector for cancer vaccines. Full Text | PDF You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2011 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.